SCHEMBL714760

SCHEMBL714760

CNC(=O)C1CCCNC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A1 P30531 2/20 0.59
SLC6A11 P48066 1/20 0.59
TSHR P16473 1/20 0.59
LMNA P02545 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
SLC6A13 Q9NSD5 1/20 0.59
KDM4E B2RXH2 1/20 0.57
MAPT P10636 1/20 0.57
KMT2A Q03164 1/20 0.57
ATM Q13315 1/20 0.57
CYP2D6 P10635 1/20 0.57
CHRNB2 P17787 2/20 0.50
CHRNA4 P43681 2/20 0.50
CHRNA7 P36544 1/20 0.50
CHRNB4 P30926 1/20 0.48
CHRNA3 P32297 1/20 0.48
NOS2 P35228 1/20 0.47
TNKS O95271 1/20 0.42
TNKS2 Q9H2K2 1/20 0.42
ULK1 O75385 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1088191 1.00 SLC6A1 (0.59) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
SCHEMBL1088241 1.00 SLC6A1 (0.59) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
Hydrochloric Acid SCHEMBL5908246 0.98 SLC6A1 (0.57) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
SCHEMBL4125597 0.88
SCHEMBL15082262 0.88
SCHEMBL2916439 0.88
Hydrochloric Acid SCHEMBL23779176 0.86 CHRNB2 (0.52) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
Hydrochloric Acid SCHEMBL30751515 0.86 CHRNB2 (0.52) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
SCHEMBL2918867 0.83 CHRNB2 (0.57) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
SCHEMBL13485777 0.82 SLC6A1 (0.61) SLC6A1SLC6A11TSHRLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4013755-B1 PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS NOVARTIS AG (CH) 2025-01-08 EP claimed
CN-117881397-A Heterocyclic compounds and methods of use 安进公司 2024-04-12 CN claimed
CN-111601798-B Bisamide sarcomere activating compounds and uses thereof 美国安进公司 2023-08-11 CN claimed
US-11420970-B1 Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents NOVARTIS AG (CH) 2022-08-23 US claimed
EP-2627650-A2 N-PHENYL IMIDAZOLE CARBOXAMIDE INHIBITORS OF 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 Merck Sharp & Dohme Corp. (US) 2013-08-21 EP claimed
WO-2011149874-A2 N-PHENYL IMIDAZOLE CARBOXAMIDE INHIBITORS OF 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 SCHERING CORPORATION (US) 2011-12-01 WO claimed
US-20100104659-A1 BENZOPYRANOPYRAZOLES 4SC AG (DE) 2010-04-29 US claimed
EP-0863757-B1 2-SUBSTITUTED ARYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK & CO INC (US) 2003-03-26 EP claimed
EP-0863757-A1 2-SUBSTITUTED ARYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE Merck & Co., Inc. (US) 1998-09-16 EP claimed
EP-0863757-A4 1998-09-16 EP claimed
US-5792778-A TREATMENT OF CYTOKINE MEDIATED DISEASES MERCK & CO., INC. (US) 1998-08-11 US claimed
WO-1997005877-A1 2-SUBSTITUTED ARYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK & CO., INC. (US) 1997-02-20 WO claimed
US-20260109698-A1 MALT-1 MODULATORS EXSCIENTIA AI LIMITED (GB) 2026-04-23 US disclosed
US-12312353-B2 Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents NOVARTIS AG (CH) 2025-05-27 US disclosed
CN-119894513-A Heterocycles as modulators of NSD activity 德州大学系统董事会 2025-04-25 CN disclosed
US-20250051327-A1 MALT-1 MODULATORS RECURSION PHARMACEUTICALS, INC. 2025-02-13 US disclosed
US-5792778-A TREATMENT OF CYTOKINE MEDIATED DISEASES MERCK & CO., INC. (US) 1998-08-11 US disclosed
WO-1997005877-A1 2-SUBSTITUTED ARYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK & CO., INC. (US) 1997-02-20 WO disclosed
EP-0252503-B1 AMINOIMIDAZOQUINOLINE DERIVATIVES Bristol-Myers Squibb Company (US) 1992-11-19 EP disclosed
EP-0252503-A1 Aminoimidazoquinoline derivatives Bristol-Myers Squibb Company (US) 1988-01-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12312353-B2 Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents NSD2, NSD1, NSD3 SLC6A1 3395/4885SLC6A11 3458/4885TSHR 4665/4885
US-11420970-B1 Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents NSD2, NSD1, NSD3 SLC6A1 3395/4885SLC6A11 3458/4885TSHR 4665/4885
US-20250051327-A1 MALT-1 MODULATORS MALT1, BCL6, BCL9 SLC6A1 3536/4885SLC6A11 4068/4885TSHR 4555/4885
US-20100104659-A1 BENZOPYRANOPYRAZOLES BAX, BCL2, BAD SLC6A1 4186/4885SLC6A11 4365/4885TSHR 2013/4885
US-20260109698-A1 MALT-1 MODULATORS MALT1, BCL6, BCL3 SLC6A1 988/4885SLC6A11 1644/4885TSHR 2213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.